COSCIENS Biopharma Inc. (TSX:CSCI)

Market Cap	13.65M
Revenue (ttm)	13.79M
Net Income (ttm)	-22.03M
Shares Out	3.15M
EPS (ttm)	-8.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,039
Average Volume	930
Open	4.260
Previous Close	4.160
Day's Range	4.260 - 4.340
52-Week Range	2.900 - 15.130
Beta	2.27
RSI	51.34
Earnings Date	Mar 26, 2025

About COSCIENS Biopharma

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1990
• Employees: 40
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: CSCI

Financial Performance

In 2024, COSCIENS Biopharma's revenue was $9.59 million, an increase of 34.22% compared to the previous year's $7.14 million. Losses were -$15.31 million, 339.3% more than in 2023.

Financial numbers in USD